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Abstract: Vaccination plays a key role in reducing morbidity and mortality caused by infectious
diseases, including the recent COVID-19 pandemic. However, a comprehensive approach that allows
the planning of vaccination campaigns and the estimation of the resources required to deliver and
administer COVID-19 vaccines is lacking. This work implements a new framework that supports
the planning and delivery of vaccination campaigns. Firstly, the framework segments and priorities
target populations, then estimates vaccination timeframe and workforce requirements, and lastly
predicts logistics costs and facilitates the distribution of vaccines from manufacturing plants to
vaccination centres. The outcomes from this study reveal the necessary resources required and their
associated costs ahead of a vaccination campaign. Analysis of results shows that by integrating
demand stratification, administration, and the supply chain, the synergy amongst these activities
can be exploited to allow planning and cost-effective delivery of a vaccination campaign against
COVID-19 and demonstrates how to sustain high rates of vaccination in a resource-efficient fashion.
Keywords: SARS-CoV-2 vaccines; vaccination campaign; vaccine availability; demand stratification;
economic analysis; mathematical programming
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus that causes
the coronavirus 2019 (COVID-19) disease, was first identified in December 2019 [1,2]. Due
to the rapid spread and highly contagious nature of this new coronavirus, the World
Health Organisation (WHO) declared COVID-19 a pandemic on 11 March 2020 [1–4],
prompting governments around the world to take swift measures aimed at mitigating the
economic, health, and social impacts of the disease. Supported by governments and non-
governmental organisations [5–8], pharmaceutical companies and academic institutions
have deployed a range of platform technologies to produce COVID-19 vaccines in record
time, including: (i) viral vectors such as AZD1222 (ChAdOx1 nCoV2) developed by
University of Oxford and AstraZeneca [9,10], Ad26.COV2.S developed by Johnson and
Johnson [11–13], and Sputnik V (rAd26 and rAd5) developed by Gamaleya Research
Institute [14–16]; (ii) nucleic-acid-based vaccines such as BNT162b2 developed by Pfizer and
BioNTech [17–19], mRNA-1273 developed by Moderna [20–22], and CVnCoV developed by
CureVac [23]; (iii) inactivated pathogens such as BBIBP-CorV developed by Sinopharm [24];
(iv) protein subunits such as NVX-CoV2373 developed by Novavax [25,26].
Despite the successes recorded in the development of vaccines against SARS-CoV-2,
many challenges remain in the deployment and administration of COVID-19 vaccines in
both low- and middle-income countries (LMICs) and high-income countries (HICs) [27–32].
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Key challenges include (i) the need to vaccinate the world population rapidly to achieve
herd immunity; (ii) scaling-up vaccine manufacturing capacity and the vaccine supply
chain to meet the global demand for SARS-CoV-2 vaccines; (iii) developing supply chains
capable of handling viral vectors, nucleic-acid-based vaccines, inactivated pathogens, and
protein subunits; and (iv) building resilience in vaccine supply chains that can simultane-
ously handle routine immunisation and mass vaccination campaigns against infectious
diseases such as COVID-19. Another activity to be conducted before the implementation
of a mass vaccination campaign is the assessment of the relative risks and benefits of the
intervention, taking into account the following: (i) the potential impact of the vaccine-
preventable disease or high-impact disease outbreak using key epidemiological criteria;
(ii) the potential benefits of a mass vaccination campaign and the country’s capacity to
implement it safely and effectively; (iii) the potential risk of increased COVID-19 trans-
mission associated with the mass vaccination campaign; (iv) determination of the most
appropriate actions considering the epidemiological situation related to COVID-19; and
(v) implementation of best practice if a decision is made to proceed with a mass vaccina-
tion campaign [33]. The detailed standard criteria recommended by the WHO on how
to assess the risks and benefits of conducting a mass vaccination campaign can be found
elsewhere [33].
The use of mathematical models to address these challenges and to inform decision-
making related to public health has intensified in recent years. Such models have been
developed and applied to facilitate understanding and to analyse the spread of infectious
diseases [34–39], vaccine manufacture processes [40–45], and vaccine supply chains [46–49].
Vaccine supply chains in particular are complex networks that store and transport vaccines
under controlled temperature from manufacturing plants to vaccination centres. There are
two categories of models typically employed to describe them: simulation-based models
and optimisation-based models. The former evaluate one vaccine distribution scenario
at a time and can be used in designing new supply chains or re-designing existing ones
to improve a specific performance indicator such as cost or vaccine availability [49–51].
In contrast, optimisation-based models support the use of optimisation algorithms to
identify the best candidate supply chain among multiple alternatives. The advantages
of optimisation-based models include the optimal selection of locations for entities such
as manufacturing plants, warehouses, and regional stores; the identification of transport
routes that minimise delivery time and transportation costs; the determination of the
target capacities of manufacturing plants, fill-finish plants, warehouses, and administration
points; and supporting the evaluation of several key performance indicators, such as the
total logistic costs, vaccine availability, lead time, and storage capacity utilisation.
Optimisation-based models have been used to design and plan sustainable vaccine
supply chains [52]; to investigate the impact of uncertain parameters such as vaccine
demand on supply chain performance [53]; to plan the distribution for an expanded pro-
gramme of immunisation vaccines in LMICs [54]; to assess the performance of vaccine
supply chains in LMICs, considering the distribution of vaccines produced using new
manufacturing technologies such as RNA vaccines, outer membrane vesicle vaccines
with genetically customisable membrane antigens (customOMV), virus-like particle vac-
cines with genetically configurable epitopes (customVLP), and humanised yeast-produced
vaccines [55]; and to plan the distribution of COVID-19 vaccines during the ongoing pan-
demic [56]. These previous studies have focused on the design and analyses of vaccine
supply chains only, without considering vaccine demand stratification and the planning
of vaccine administration. Ahead of a mass vaccination campaign, demand stratification
may be applied to segment and prioritise a target population in order to maximise the
effectiveness of vaccination, while the planning of vaccine administration involves estima-
tion of the vaccination timeframe and regional workforce requirements in order to avoid
failure to meet vaccination targets and to reduce vaccine wastage and the number of missed
vaccination opportunities at clinics, hospitals, pharmacies, and vaccination centres. A lack
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of proper planning could compromise the effectiveness of vaccination, leading to a surge
in the number of cases and increased death and hospitalisation rates.
Additionally, models presented in previous works do not support (i) the handling
of passive cold chain devices such as thermal shippers, (ii) quality control testing at
warehouses, or (iii) vaccine supply from in-country and overseas manufacturing and fill-
finish facilities. These are essential components of a typical vaccine supply chain that
should be taken into account in order to maintain integrity of vaccines throughout the cold
chain and to ensure that safe, potent, and efficacious vaccines are delivered to the right
places and at the right time, especially during a pandemic.
This paper presents an optimisation-based model for vaccine supply chains, which
is embedded within a systematic framework combining vaccine demand stratification,
vaccine administration, and vaccine supply and delivery. A distinctive feature of our
supply chain model is that it considers the storage and transportation of vaccines at both
refrigerated and ultra-low temperatures, which is an essential requirement for nucleic-
acid-based vaccines (e.g., mRNA vaccines), as well as the handling of passive cold chain
devices such as vaccine thermal shippers during a vaccination campaign. The model also
includes quality control test capabilities at warehouses, such that each batch of vaccine is
tested before distribution to vaccination centres and can handle various types of vaccines,
such as viral vectors, nucleic-acid-based vaccines, inactivated pathogens, protein subunits,
and conjugate vaccines. We use real-world data to demonstrate the applicability of the
proposed framework, focusing on determining the resources required, from a supply chain
and vaccine administration perspective, to vaccinate up to 500,000 patients per day against
COVID-19 within the UK.
The remainder of this article is organised as follows. Section 2 introduces the case
study on COVID-19 vaccination in the UK, which is used to demonstrate the applicability
of the proposed framework. Section 3 outlines the proposed framework and discusses, in




Figure 1 shows the proposed systematic framework that supports vaccine supply and
administration. The framework comprises three distinct steps that model vaccine demand
stratification, vaccine administration, and vaccine supply and delivery.




Figure 1. Modelling framework for the supply, distribution, and administration of COVID-19 vaccine, showing the 
direction of information. 
Step 1. Given the total population of a geographical area and cohort size, the demand 
stratification model estimates the number of individuals belonging to each cohort in all 
regions within a geographical area; see Supplementary 4 for further information. This 
information is critical since it enables a specific segment of a population to be targeted 
during a vaccination campaign against infectious diseases; 
Step 2. The vaccine administration model computes the duration needed to vaccinate 
each cohort determined in step 1, the vaccination schedule, and the total number of 
healthcare personnel needed to implement the vaccination exercise see Supplementary 4 
for further information. In addition to stratified demand for all regions, other inputs to 
this model include staff working hours per day, vaccine administration rate, and patients 
vaccinated per day; 
Step 3. The vaccine supply chain model makes use of information determined from 
the demand stratification and vaccine administration in steps 1 and 2 to predict logistics 
operations and costs and to optimise the supply, delivery, and administration of various 
vaccine candidates; see Section 2.2 below and Supplementary 3 for further details. 
Demand stratification, vaccine administration, and vaccine supply and distribution 
are inter-dependent. For example, modifying the target population or cohort size will 
affect workforce requirements and the vaccination timeframe, which in turn will affect 
vaccine supply, and ultimately logistics cost. Using the proposed framework, the 
synergies amongst these activities can be exploited to minimise logistics cost and to allow 
efficient planning and delivery of a vaccination campaign. This cannot be achieved using 
previously published methodologies. 
2.2. Vaccine Supply Chain Modelling 
The cornerstone of the modelling framework is a mixed-integer linear programming 
(MILP) model describing a multi-echelon supply chain (see Figure 2) for the distribution 
and delivery of vaccine candidates from plants to vaccination centres. 
Figure 1. Modelling framework for the supply, distribution, and administration of COVID-19 vaccine, showing the direction
of information.
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Step 1. Given the total population of a geographical area and cohort size, the demand
stratification model estimates the number of individuals belonging to each cohort in all
regions within a geographical area; see Supplementary 4 for further information. This
information is critical since it enables a specific segment of a population to be targeted
during a vaccination campaign against infectious diseases;
Step 2. The vaccine administration model computes the duration needed to vaccinate
each cohort determined in step 1, the vaccination schedule, and the total number of
healthcare personnel needed to implement the vaccination exercise see Supplementary 4
for further information. In addition to stratified demand for all regions, other inputs to
this model include staff working hours per day, vaccine administration rate, and patients
vaccinated per day;
Step 3. The vaccine supply chain model makes use of information determined from
the demand stratification and vaccine administration in steps 1 and 2 to predict logistics
operations and costs and to optimise the supply, delivery, and administration of various
vaccine candidates; see Section 2.2 below and Supplementary 3 for further details.
Demand stratification, vaccine administration, and vaccine supply and distribution
are inter-dependent. For example, modifying the target population or cohort size will
affect workforce requirements and the vaccination timeframe, which in turn will affect
vaccine supply, and ultimately logistics cost. Using the proposed framework, the synergies
amongst these activities can be exploited to minimise logistics cost and to allow efficient
planning and delivery of a vaccination campaign. This cannot be achieved using previously
published methodologies.
2.2. Vaccine Supply Chain Modelling
The cornerstone of the modelling framework is a mixed-integer linear programming
(MILP) model describing a multi-echelon supply chain (see Figure 2) for the distribution
and delivery of vaccine candidates from plants to vaccination centres.




Figure 2. Schematic of the proposed vaccine supply chain comprising internal and external manufacturing and fill-finish 
plants, in-country warehouses, regional vaccine stores, and administration points (GP surgeries, hospitals, pharmacies, 
vaccination centres, etc.). Vaccines flow from manufacturing facilities to administration points via transport devices 
(plane, refrigerated van, refrigerated truck, etc.). The flows of vaccines and thermal shippers are indicated by the blue and 
red lines, respectively. The orange line indicates the flow of vaccines out of the supply chain for administration to target 
vaccinees. 
The supply chain comprises five echelons: manufacturing, fill-finish, warehouse, 
regional store, and administration point. Vaccine manufacturing and fill-finish can be 
carried either in-country, abroad, or both. Vaccine drug substances flow from 
manufacturing plants to fill-finish plants, where they are filled into sterile glass vials or 
bags and packaged into cartons. The packaged vaccines are then shipped to warehouses, 
followed by regional stores. Administration points (GP surgeries, hospitals, pharmacies, 
vaccination centres, etc.) receive vaccines from regional stores based on demand, which is 
determined by the number of appointments registered. Throughout the supply chain, in-
country distributions are fulfilled using refrigerated vans or refrigerated trucks, while 
vaccine imports are carried out using air freight. 
The mathematical formulation of the supply chain model developed in this work is 
presented in Supplementary 3. Essential input parameters to the model include: 
1. Vaccine demand profile; 
2. Vaccination timeframe; 
3. Supply chain superstructure; 
4. Minimum and maximum inventories (manufacturing and fill-finish, warehouses, 
regional stores, and administration points); 
5. Minimum and maximum capacities of manufacturing plants, fill-finish plants, and 
import rate; 
6. Minimum and maximum capacities of transportation modes, operating costs and 
capital cost factors (manufacturing and fill-finish, warehouses, regional stores, and 
administration points); 
7. Travel distances and times. 
Using these inputs, the model calculates the following outputs: 
1. Optimal supply chain structure; 
2. Transport mode per route; 
3. Backlog in each time period; 
4. Vaccine availability and vaccine wastage at administration points; 
5. Vaccine supplied to administration points per time period; 
6. Vaccine import rate and production rates in manufacturing and fill-finish plants; 
7. Capacity of quality control facilities; 
fi fi
la ts, i -co try are o ses, regio al vacci e stores, a a i istratio oi ts ( s rgeries, os itals, ar acies,
vaccination centres, etc.). Vaccines flow from manufacturing facilities to administration points via transport devices (plane,
refrigerated van, refrigerated truck, etc.). The flows of vaccines and thermal shippers are indicated by the blue and red lines,
respectively. The orange line indicates the flow of vaccines out of the supply chain for administration to target vaccinees.
The supply chain comprises five echelons: manufacturing, fill-finish, warehouse, re-
gional store, and admi istration point. Vaccine manufacturing a d fill-finish can be carried
either in-country, abroad, or both. Vaccine drug substances flow from manufacturing plants
to fill-finish plants, where they are filled int sterile glass vials or bag d packaged into
cartons. The packaged vaccine are then shipped to warehouses, follow d by regional
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stores. Administration points (GP surgeries, hospitals, pharmacies, vaccination centres,
etc.) receive vaccines from regional stores based on demand, which is determined by the
number of appointments registered. Throughout the supply chain, in-country distributions
are fulfilled using refrigerated vans or refrigerated trucks, while vaccine imports are carried
out using air freight.
The mathematical formulation of the supply chain model developed in this work is
presented in Supplementary 3. Essential input parameters to the model include:
1. Vaccine demand profile;
2. Vaccination timeframe;
3. Supply chain superstructure;
4. Minimum and maximum inventories (manufacturing and fill-finish, warehouses,
regional stores, and administration points);
5. Minimum and maximum capacities of manufacturing plants, fill-finish plants, and
import rate;
6. Minimum and maximum capacities of transportation modes, operating costs and
capital cost factors (manufacturing and fill-finish, warehouses, regional stores, and
administration points);
7. Travel distances and times.
Using these inputs, the model calculates the following outputs:
1. Optimal supply chain structure;
2. Transport mode per route;
3. Backlog in each time period;
4. Vaccine availability and vaccine wastage at administration points;
5. Vaccine supplied to administration points per time period;
6. Vaccine import rate and production rates in manufacturing and fill-finish plants;
7. Capacity of quality control facilities;
8. Capital costs, operating costs, and total annualised cost of supply chain facilities;
9. Total transportation costs and transport costs per route;
10. Inventories of vaccines in manufacturing facilities, fill-finish facilities, warehouses,
regional stores, and administration points;
11. Inventories of vaccine thermal shippers (full and empty) in warehouses, regional
stores, and administration points (needed only for vaccines stored and transported at
ultra-low temperatures).
In addition to optimising the flow of vaccines from manufacturing plants to administra-
tion points, the model can also be used to optimise the supply chain structure and operation,
as well as to determine the best vaccination plan over a given time horizon. The optimisation
of the vaccine supply chain enables improvement of key performance indicators such as
the backlog, total investment cost, vaccine availability, lead time, cost per fully immunised
patient, and logistic cost per dose. The type of objective function to be employed depends
on the intended purpose of the vaccine supply chain or vaccination programme.
This work focuses on minimisation of the total annualised logistics cost and minimisa-
tion of the backlog, owing to their relevance not only in vaccine supply and distribution but
also in other healthcare supply chains. Total annualised logistics cost is the sum of installed
capital costs, operating costs, and transportation costs, while the backlog is the sum of
unfulfilled or late vaccination or failed appointments over the entire vaccination period.
Although this work aims to investigate the impact of vaccine supply chain operational and
structural decisions on total annualised logistics costs and the backlog, the proposed model
can also estimate other key performance indicators, including the logistics cost per fully
immunised patient, logistics cost per dose, capacity utilisation, vaccine availability, vaccine
wastage, and demand satisfaction.
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2.3. Data Sources and Assumptions
2.3.1. Demand Stratification
The essential information required to carry out a demand stratification is the geo-
graphical population and target group or cohort size information. Herein, we make use
of data provided by the UK’s Office for National Statistics [57]. These data include five
age cohort populations in 12 regions, namely the North East, North West, Yorkshire and
the Humber, East Midlands, West Midlands, East, London, South East, South West, Wales,
Northern Ireland, and Scotland. The population data are from 2020 population estimates,
while stratification is conducted in agreement with the cohort size recommended by the
Joint Committee on Vaccination and Immunisation (JCVI) [58].
2.3.2. Vaccine Administration
In addition to the demand stratification, this step requires data on staff working
hours per day, vaccine administration rate, and patients vaccinated per day (UK target).
Herein, we assume that staff should work at least six hours a day and spend ten min
vaccinating each patient, including screening and consent activities [59–61]. Following the
UK government vaccination campaign ambitions, we assume a daily vaccination rate of
500,000 patients per day across the UK [62–64]. According to the British Medical Association
(BMA), the cost of administrating a vaccine at GP surgeries, hospitals, pharmacies, and
vaccination centres is equivalent to $16.80 (£12.58) per dose, while vaccines administered at
care homes incur an extra $13.36 (£10) per dose [65]. We assume that care home residents
and residential care workers are vaccinated within the premises of care homes.
2.3.3. Vaccine Supply Chain
This is the most computationally demanding step of the framework and it requires an
extensive input dataset. Since the model is driven by demand at vaccination centres or care
homes, information related to the demand profile needs to be specified. The demand profile
at each vaccination centre across the UK is fixed by the number of weekly appointments,
which can be calculated using stratified demand or the number of individuals arriving at
clinics in order to be inoculated with a jab. In our initial studies, we assume 100% coverage
in all geographical regions in the UK. A vaccination schedule can be defined from the
estimated time required to vaccinate each cohort in addition to the intervals between doses.
The supply chain structure is configured to mimic the existing vaccine supply and
distribution network in the UK and is represented in Figure 3. The network consists of
manufacturing and fill-finish plants co-located in Puur, Belgium; four warehouses located
in London, Cardiff, Edinburgh, and Belfast; and 12 regional stores located in Cardiff,
Edinburgh, Belfast, and the nine regions in England (North East, North West, Yorkshire
and the Humber, East Midlands, West Midlands, East of England, London, South East,
South West). Within the UK, the government aims to established several vaccination centres
within a ten-mile radius of the surrounding populace [66], leading to spatially distributed
vaccine administration points. To reduce the computational load during simulation and
optimisation studies, we group all vaccination centres in each region.
The working assumption is that sufficient vaccines can be supplied from plants
on weekly basis, meaning there is no limitation on vaccine import from manufacturing
facilities. However, there are limitations on the capacity of storage facilities at each level of
the supply chain. The four warehouses located in London, Cardiff, Edinburgh, and Belfast
have a maximum capacity of 150 m3, which is equivalent to 8.23 million doses. The twelve
regional stores have maximum capacities of 90 m3, which is equivalent to 4.94 million
doses. Lastly, the cluster of vaccination centres in Wales, Scotland, Northern Ireland, and
the nine regions in England have storage capacities of 30 m3, equivalent to 1.65 million
doses. Using this information, we estimated the installation and operating costs associated
with each storage facility. For warehouses and regional stores, the installation costs are
equivalent to $28,700 facility−1 week−1 and $17,200 facility−1 week−1 and the operating
costs are $0.0098 dose−1 week−1 and $0.0129 dose−1 week−1, respectively. The facility
Vaccines 2021, 9, 1460 7 of 19
installation cost takes into account the cost of building as well as the purchase cost of
refrigerators and freezers. We assumed that cold chain equipment occupies about 70%
of the total flow area of warehouses and regional stores. The remaining 30% is used for
office equipment and space for installing ancillary devices. Operating costs comprise staff
wages and the cost for the electricity required to power the cold chain equipment. The cost
of quality control checks at warehouses is estimated using information provided by the
National Institute for Biological Standard and Control (NIBSC) [67].
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Figure 3. Supply chain for the distribution and delivery of the BNT162b2 SARS-CoV-2 vaccine candidate across the UK. No
in-country vaccine manufacture or fill-finish facilities.
Vaccines are airlifted from plants to warehouses, while domestic distribution is carried
out using either a refrigerated van or a refriger ted truck. The airfr ight rate is ab ut
$3.26 kg−1 [68]. The maximum weight per trip is fixed at 21,000 kg [69], which is equivalent
to 24.6 million doses per t ip and $0.00278 per dose. Domestic transport by refrigerat d
van and refrigerated truck costs $0.10 km−1 nd $0.26 km−1 respectively. These costs
account for fuel, the annualised capital cost of vehicle, driver’s wages, and the average
annual dista ce travelled by vehicle. Travel distances between supply chain enti ies were
estimated u ing Google Maps, assuming straight lines between facilities, while travel
times were calculated by dividing the travel distance by the average vehicle speed, as
recommended by the Department of Transport UK [70].
Our case study investigates the supply and distribution of nucleic-acid-based SARS-
CoV-2 vaccine candidate BNT162b2 developed and manufactured by Pfizer and BioNTech.
Table S1 of Supplementary Materials summarises the characteristics of this vaccine.
3. Results and Discussions
3.1. Vaccine Demand Stratification
Prior to conducting the COVID-19 vaccination campaign, the target population in a
geographical region needs to be grouped and prioritised to increase the effectiveness of
vaccination and to mitigate the impacts of infectious disease. According to the JCVI, the
vaccination of the UK populace is being carried out in two phases. Phase 1 aims at direct
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prevention of mortality and focuses on vaccination of care home residents, residential care
workers, those aged 80 plus, healthcare workers, social care workers, those aged 75–79,
those aged 70–74, clinically extremely vulnerable individuals (under 70), those aged 65–69,
at risk individuals (under 65), those aged 60–64, those aged 55–59, and those aged 50–54.
Then, phase 2 aims to further reduce hospitalisation through vaccination of the rest of the
adult population aged 18–49. Table S2 of Supplementary Materials shows the complete
JCVI cohort classification into priority groups. This information together with the UK
population data is used for inputs to the demand stratification model. Figure 4 shows the
stratified UK population data according to the JCVI cohorts.




Figure 4. Target adult population in the UK and the distribution in accordance with cohorts recommended by the Joint 
Committee on Vaccination and Immunisation. Percentages are relative to the total target population. 
The target population corresponds to about 53 million individuals across the UK, out 
of which 39% are individuals aged 18–49. According to this baseline scenario, only healthy 
individuals aged below 18 are not considered. Apart from targeting the most vulnerable, 
vaccinating 80% of the UK population is needed to achieve herd immunity [71–73]. The 
results shown in Figure 4 indicate not only the target population but also provide a basis 
for estimating, in advance, the total doses required for the vaccination campaign and the 
number of doses allocated to each cohort. Knowing in advance the number of doses 
allocated to each cohort can allow government and policy-makers to set out an effective 
vaccination strategy that would focus on the most vulnerable individuals, especially when 
vaccines are under limited supply. 
Figure 4 can be used together with Figure S1 of Supplementary Materials to 
understand regional vaccine demand within the UK based on cohorts recommended by 
JCVI. There is no significant variation in the distribution of care home residence and 
residential care workers across regions. A similar trend is observed in the distribution of 
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Apart from visualising and estimating the demand of BNT162b2 SARS-CoV-2 
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A vaccination campaign is always preceded by vaccine demand and workforce 
planning in order to meet the vaccination target. The vaccination timeframe required to 
vaccinate each cohort can be calculated by dividing the target population by the 
vaccination rate, where the latter takes into account staff working hours, time taken to 
vaccinate each patient, and daily vaccination target. 
Figure 5 shows the duration (in weeks) to vaccinate each cohort in the UK. Phase 1 
of the vaccination exercise takes about 23 weeks, while phase 2 takes about 12 weeks. This 
indicates that the total duration of the vaccination exercise is about 38 weeks, considering 
that prime and booster doses are administered 3 weeks apart. Estimates of the duration 
Figure 4. Target adult popul tion in the UK and the dist ibution in acc rdance with cohorts recom-
me ded by the Joint Committe on V ccin tion nd Immunisation. Percentages are relative to the
total target population.
The target population corresponds to about 53 million individuals across the UK, out
of which 39% are individuals aged 18–49. According to this baseline scenario, only healthy
individuals aged below 18 are not considered. Apart from targeting the most vulnerable,
vaccinating 80% of the UK population is needed to achieve herd immunity [71–73]. The
results shown in Figure 4 indicate not only the target population but also provide a basis
for estimating, in advance, the total doses required for the vaccination campaign and
the number of doses allocated to each cohort. Knowing in advance the number of doses
allocated to each cohort can allow government and policy-makers to set out an effective
vaccination strategy that would focus on the most vulnerable individuals, especially when
vaccines are under limited supply.
Figure 4 can be used together with Figure S1 of Supplementary Materials to under-
stand regional vaccine demand within the UK based on cohorts recommended by JCVI.
There is no significant variation in the distribution of care home residence and residential
care workers across regions. A similar trend is observed in the distribution of clinically
extremely vulnerable individuals under 70, social care workers, and individuals aged 75–79.
By contrast, the distribution of the rest of adult population, individuals at risk under 65,
individuals aged 80 and over, individuals aged 70–74, individuals aged 65–69, individuals
aged 50–54, and individuals aged 55–59 varies visibly across regions.
Apart from visualising and estimating the demand of BNT162b2 SARS-CoV-2 vaccines
in various regions within the UK, Figure S1 can be used to establish a supply plan for re-
gions with the most vulnerable populations. Looking forward, the information in Figure S1
could also be used to estimate regional demand for booster vaccination campaigns targeted
at vulnerable individuals.
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3.2. Vaccine Administration
A vaccination campaign is always preceded by vaccine demand and workforce plan-
ning in order to meet the vaccination target. The vaccination timeframe required to vacci-
nate each cohort can be calculated by dividing the target population by the vaccination
rate, where the latter takes into account staff working hours, time taken to vaccinate each
patient, and daily vaccination target.
Figure 5 shows the duration (in weeks) to vaccinate each cohort in the UK. Phase 1 of
the vaccination exercise takes about 23 weeks, while phase 2 takes about 12 weeks. This
indicates that the total duration of the vaccination exercise is about 38 weeks, considering
that prime and booster doses are administered 3 weeks apart. Estimates of the duration
required to vaccinate each JCVI cohort can be used to inform decision-making on when to
start easing lockdown restrictions as vaccination progresses, especially when the high-risk
groups have been vaccinated.
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A successful vaccination campaign requires a sufficient number of healthcare workers.
The number of healthcare workers required for the vaccination exercise across the regions is
considered. The overall staff requirement numbers across the UK range between 23,896 and
97,466. London requires the highest number of healthcare workers (range: 2068–15,986),
whilst Northern Ireland has the lowest staff requirements (range: 800–3627). Staff re-
quirements in other regions are as follows: North East (range: 965–4076), North West
(range: 2498–10,759), Yorkshire and the Humber (range: 1900–8144), East Midlands (range:
1690–7214), West Midlands (range: 2077–8862), East of England (range: 2382–9883), South
East (range: 3488–14,497), South West (range: 2377–9567), Wales (range: 1118–5084), and
Scotland (range: 2083–11,222).
Ahead of a COVID-19 vaccination campaign, the estimated number of healthcare
workers can be used by government and policy-makers to assess workforce requirements.
For example, by comparing the staff requirement estimates against the existing workforce
across regions in the UK, it is possible to identify regions with shortfalls and take measures
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by recruiting additional staff or re-directing staff from regions with surplus workforce. In
addition, knowing the workforce requirements in advance can ensure efficient financial
planning, thereby keeping staff wages within an overall budget. Recall that the results
presented in Figure 5 assumes that each staff member works a six-hour shift and spends at
most ten minutes to vaccinate each patient (including screening, obtaining consent, etc.),
meaning results will vary for different work patterns.
To meet the COVID-19 vaccination target of 500,000 patients per day across the UK,
it is necessary to vaccinate between 860,250 and 3,508,792 individuals on a weekly basis.
The largest weekly vaccination target is observed in London (range: 74,450–575,482), while
the lowest is observed in Northern Ireland (range: 28,800–130,583). Weekly vaccination
targets in the other regions are as follows: North east (range: 34,753–146,729), North west
(range: 89,914–387,321), Yorkshire and the Humber (range: 68,390–293,166), East Midlands
(range: 60,827–259,706), West Midlands (range: 74,769–319,050), East of England (range:
85,753–355,800), South East (range: 125,574–521,877), South West (range: 85,571–344,416),
Wales (range: 40,250–183,017), and Scotland (range: 75,000–404,000). Naturally, regions
with large numbers of individuals to be vaccinated require large numbers of HCWs, and
vice versa. The weekly vaccinations give an indication about the capacity of vaccine
administration points that would be needed in Wales, Scotland, Northern Ireland, and the
nine regions in England.
A vaccination campaign may not proceed without sufficient supply of vaccines from
manufacturing plants. Using information on weekly vaccination targets and vaccine doses
needed to fully immunise each patient (in this case 2 doses administered 3 weeks apart),
the vaccine demand profile during a COVID-19 vaccination campaign in the UK can
be estimated.
Figure 6 shows the number of doses that should be made available per week in the
UK to meet the timeframe set out in Figure 5. The demand for the BNT162b2 SARS-
CoV-2 vaccine varies on a weekly basis throughout the vaccination period and ranges
between 0.86 and 3.51 million doses per week. This demand profile can serve as an
important tool not only for guiding government and policy-makers on securing contracts
for vaccine supply from manufacturers or contract manufacturing organisations, but also
for developing supply plans during the vaccination period to meet the target of vaccinating
up to 500,000 patients per day. Over-supply could lead to vaccine wastage, which can have
a significant cost implication, while low supply can lead to shortfalls, which can lead to a
surge in infection. The vaccine demand profile can also be used in designing a new vaccine
supply chain or re-designing an existing supply chain to meet the COVID-19 vaccination
target across the UK.
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3.3. Vaccine Supply Chain Optimisation
Using the demand profile shown in Figure 6, information presented in Section 3.3,
and the supply chain model in Section 3.2, an optimisation study is carried out for the
supply chain in Figure 3 to meet COVID-19 vaccination target of up to 500,000 patients per
day across the UK. To investigate the impacts of vaccine shortage on logistics and vaccine
administration, a bi-objective optimisation model [74] is set up considering the logistics
cost and backlog as objectives. The accumulation of backlog as a result of vaccine shortage
can impact the logistics cost and logistics cost per fully immunised patient (FIP), as well as
vaccine availability in England, Scotland, Wales, and Northern Ireland.
The supply chain optimisation results are illustrated on Figure 7 and further discussed
below. The flow of BNT162b2 SARS-CoV-2 vaccines from the factory in Puur, Belgium, to
warehouses in London, Cardiff, Edinburgh, and Belfast is shown in Figure S2 of Supple-
mentary Materials; the quality control capacity required at warehouses across the UK in
Figure S3; the weekly flow of vaccine shippers from warehouses to vaccination centres and
back to warehouses in Figure S4; and the total trips covered by transportation modes at
various levels of the supply chain in Figure S5.
The Pareto frontier shown in Figure 7A comprises non-dominated points in the bi-
objective optimisation model. For these points, it is not possible to make improvement to
the total logistics cost without worsening backlog, and vice versa. Each point on the Pareto
frontier represents an alternative vaccine supply chain design and its associated operating
strategy. Clearly, an increase in backlog is accompanied by a reduction in the total logistics
cost, and vice versa. A zero backlog means that all target individuals in England, Scotland,
Wales, and Northern Ireland have received their prime and booster jabs, leading to 100%
vaccine availability (upper extreme point of the vaccine availability curve in Figure 7B).
The impact of backlog on vaccine availability is quite pronounced. However, accumulation
of backlog during the COVID-19 vaccination campaign is not predicted to significantly
reduce the logistics cost or logistics cost per FIP.
Figure 7C,D present the total logistics costs for the delivery of the BNT162b2 SARS-
CoV-2 vaccine from the factory in Puur, Belgium, to administration points in England,
Scotland, Wales, and Northern Ireland. No operating cost is observed in scenarios 1 or
2 because vaccines are stored at clinics and vaccination centres only, with no inventories
at warehouses or regional vaccine stores. As expected, the total annualised logistics cost
obtained in scenario 2, $0.970 million week−1, is lower than that of scenario 1, $0.986
million week−1. However, this does not translate into a significant difference in logistics
cost per FIP for scenarios 1 ($0.0184 patient−1) and 2 ($0.0185 patient−1). Recall that these
estimates are calculated considering JCVI cohorts only and may vary if new cohorts for
individuals aged 17 years and under are added. It is also worth reiterating that the total
annualised logistics cost excludes the cost of vaccine shippers, cost of quality control checks
at warehouses, and cost of vaccine procurement.
Besides the total logistics cost and logistics cost per FIP, additional key performance
measures reported in Table 1 include the costs of shippers, dry ice, vaccine procurement,
quality control, and vaccinator wages. The costs of vaccinating individuals differ in
scenarios 1 and 2, since the total numbers of individuals to be vaccinated are not the
same as a result of backlog. Similarly, the cost of vaccine procurement in scenario 1 is
2% ($40 million) greater than in scenario 2. The extra cost observed in scenario 1 is due
to the supply of sufficient doses of BNT162b2 vaccines to vaccination centres across the
UK (see Section 3.4). The increase in the vaccine procurement cost is also reflected in the
cost of dry ice, since additional dry ice would be required to keep the vaccine at −80 °C
during transportation. The extra dry ice needed is approximately 11 ton when compared
to scenario 2. The cost of purchasing thermal shippers in scenario 2 is 5% ($0.330 million)
lower than in scenario 1. This results from the fact that the numbers of shippers required
are 1160 and 1110 in scenarios 1 and 2, respectively.
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Table 1. Estimated cost of vaccine supply chain components such as vaccine thermal shippers, dry
ice, vaccinator wages, vaccine procurement, and quality control checks.
Item. Scenario 1 Scenario 2 Units
Cost of vaccine shipper 7.72 7.39 million $
Cost of dry ice 20.30 19.90 million $
Cost of vaccinating individuals 1.88 1.85 billion $
Cost of vaccinating individuals at care home 24.10 24.10 million $
Cost of vaccine procured 2.00 1.96 billion $
Cost of quality control checks 59.90 58.70 million $
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From a logistics point of view, handling a small number of thermal shippers can lead
to more efficient management, as fewer shippers would be recycled during the vaccination
campaign. Furthermore, less workforce would be required to manage a small number
of shippers, leading to savings in staff wages. On the contrary, handling a large number
of thermal shippers can increase the transportation cost (and consequently total logistics
cost) as a result of the large payload that needs to be transported from warehouses to
administration points. The increase in total logistics cost can be exacerbated by capital
investment in cold chain equipment required to store vaccines and shippers at warehouses,
regional stores, and administration points. Regardless of the scenario, the cost of vaccine
procurement dominates the overall cost, followed by wages paid to vaccinate all target
individuals in England, Scotland, Wales, and Northern Ireland. Therefore, to achieve
additional cost savings, the key targets for improvement are the vaccine procurement
cost and vaccinator wages. The cost of administering vaccines to individuals is fixed at
$17.10 (£12.80) per patient, plus $13.36 (£10) when vaccines are administered in care homes.
Hence, one option to minimise the total vaccinator wages is that government needs to
either re-negotiate the unit price for administering vaccines or consider other alternatives,
for example by training and using the military or paramedics for the vaccination campaign.
The selling price of the BNT162b2 SARS-CoV-2 vaccine differs considerably across
the world, ranging between $7 and $20 per dose [32], with the UK government paying
$18.66 per dose. Considering the global selling price of BNT162b2 SARS-CoV-2 vaccines,
the cost of procuring 107 million doses (UK demand) can vary significantly—between
MM$ 750.4 and $2.14 billion, which corresponds to a 62.5% decrease and 7.2% increase
when compared to the current price the UK government is paying to procure the BNT162b2
SARS-CoV-2 vaccines. As well as re-negotiating the unit price per dose with vaccine
manufacturers, another cost saving option is to use cheaper vaccines, such as the AZD1222
SARS-CoV-2 vaccine sold for between $3 and $5 per dose [32]. Even though the cost of
vaccine procurement is high, it is of course a cheaper option compared to the economic,
social, and health impacts of coronavirus. Over one year, the lockdowns imposed by the
UK government to reduce the transmission of coronavirus have cost the UK economy in
excess of $334 (£251) billion [75]. This cost is greater than the combined cost of vaccine
procurement, vaccinator wages, vaccine thermal shippers, dry ice, quality control checks,
and logistics.
3.4. COVID-19 Vaccines Administered at Vaccination Centres
In this case study, the daily vaccination rate across the UK can rise up to 500,000 patients
per day. Figure 8 shows the weekly vaccines administered to all JCVI cohorts in Scotland,
Wales, Northern Ireland, and the nine regions in England. Note the absence of vaccination
in week 1 and week 2, as the initial batches of BNT162b2 SARS-CoV-2 vaccine undergo
quality control checks during this period.
Vaccination starts in week 3 with the care home residents, followed by residential
care workers, individuals aged 80 +, healthcare workers, social care workers, individuals
aged 75–79, individuals aged 70–74, clinically extremely vulnerable individuals (under 70),
individuals aged 65–69, at risk individuals (under 65), individuals aged 60–64, individuals
aged 55–59, individuals aged 50–54, and the rest of the adult population. The variation
in the vaccination profile across regions reflects the heterogeneity in age distribution in
the UK. The increase in the administration rate observed in week 6 is due to individuals
coming to vaccination centres for their second or booster jab. Therefore, vaccination centres
should have enough capacity to accommodate the highest weekly vaccination target. In
both scenarios 1 and 2, the required capacity rates for vaccination centres in the North East,
North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England,
London, South East, South West, Wales, Scotland, and Northern Ireland should be at least
0.147, 0.387, 0.293, 0.259, 0.319, 0.356, 0.575, 0.522, 0.344, 0.183, 0.404, and 0.131 million
doses per week, respectively.




Figure 8. Vaccine administration at various locations across the UK: (A) North East; (B) North West; (C) Yorkshire and the 
Humber; (D) East Midlands; (E) West Midlands; (F) East of England; (G) London; (H) South East; (I) South West; (J) Wales; 
(K) Scotland; (L) Northern Ireland. The blue dotted curve denotes scenario 1, whilst the red solid curve denotes scenario 
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(K) Scotland; (L) Northern Ireland. The blue dotted curve denotes scenario 1, whilst the red solid curve denotes scenario 2.
For all vaccination centres in scenario 1, logistics optimisation ensures that enough
vaccines are available to vaccinate the entire target population, leading to 100% vaccine
availability. However, in scenario 2, a shortage in vaccine supply leads to a backlog in
vaccine admi istration points, resulting in a drop in vaccine availability to 97.9% (s e
Figure 7B). The drop in vaccine availability is reflected in vaccination centres across the
UK, as shown in Figure 8. The largest shortage is observed in vaccination centres located
in Norther Ireland and Scotland, where tockouts of four weeks and three weeks r
observed, whereas in Wales, the North East, and Yo kshire nd the Humber, the stocko t
duration drops to two weeks. The remaining regions observe stockout periods of ne
week only. The variation in stockout d ration across the UK is caused by the differenc s in
dista ce between plants, warehouse , regional stores, and adminis ration points. Since the
warehouse located in London is much cl ser to the plant in Puur, Belgium, the logistics
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optimisation first satisfies the weekly demand in this location, followed by warehouses in
Wales, Scotland, and Northern Ireland. Similarly, within England, the logistics optimisation
first satisfies the weekly demand for locations closer to the warehouse in London (see
Figure 8). This results from the fact that the transportation cost dominants the logistics
cost (see Figure 7C,D); therefore, to minimise the logistics cost, the number of trips to the
farthest locations within the vaccine distribution network needs to be minimised.
The stockouts observed in vaccination centres across the UK imply that no vaccination
is conducted during these periods. In Figure 8, the stockout mostly affects individuals
aged 18–49 arriving at vaccination centres to receive their second or booster jabs. Even
though this cohort is less vulnerable to COVID-19 and the first or prime dose provides a
high protection against the novel coronavirus in addition to a reduction in transmission,
it is important to ensure that anyone willing to take the vaccine is fully immunised. This
practice can increase trust and confidence in the immunisation programme, leading to
a high acceptability rate and a reduction in vaccine hesitancy. Figure 8 demonstrates
the capabilities of the proposed vaccine distribution and administration decision support
tool, not only in monitoring the progress of a vaccination, but also in identifying regions,
locations, and cohorts that are likely to be affected should there be a shortage in vaccine
supply during the COVID-19 vaccination campaign.
4. Conclusions
We have developed a new optimisation-based vaccine supply chain model and em-
bedded this model within a systematic framework that supports the planning and delivery
of a vaccination campaign against infectious diseases. The framework consists of three
main steps. Step 1 (demand stratification) uses information on the geographical population
and cohort size to generate the stratified vaccine demand. Step 2 (vaccine administration)
utilises data on staff working hours and vaccination targets together with the stratified
demand from step 1 to estimate the vaccination timeframe, workforce needed, and indi-
viduals that must be vaccinated to meet the vaccination target. Finally, step 3 (vaccine
supply and delivery) utilises outputs from steps 1 and 2 to predict the logistics cost and
plan the distribution and administration of vaccines to targeted individuals. Optimisation
of COVID-19 vaccine supply chain indicates that minimisation of the total logistics cost
can lead to a cost-optimal vaccine supply chain that ensures a high vaccine availability at
administration points. Regardless of whether a backlog exists or not, the transportation
cost dominates the total annualised logistics cost, which can be attributed to the short
shelf life of the BNT162b2 SARS-CoV-2 vaccine. Furthermore, the estimated total cost of
supply chain components (thermal shippers, dry ice, staff wages, vaccine procurement,
and quality control checks) indicates that the cost of vaccine procurement dominates, fol-
lowed by vaccinator wages. Analysis of the impacts of backlog on other key performance
indicators by applying bi-objective optimisation indicates that an increase in backlog due to
shortage in vaccine supply or failure to meet vaccination targets does not have a significant
impact on the logistics cost and logistics cost per fully immunised patient, but can lead to
a reduction in vaccine availability (from 100 to 96 percent) in England, Scotland, Wales,
and Northern Ireland. This reduction in vaccine availability affects vaccination coverage,
thereby increasing local transmission of COVID-19, which can lead to a surge in the number
of infections, increased hospitalisation, and increased death rates across the UK.
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